Privia Health Group (PRVA) opened 2026 with Q1 revenue of US$603.8 million and net income of US$3.1 million, translating to basic EPS of US$0.02. Trailing twelve month EPS stood at US$0.18 on revenue of US$2.2 billion. Over the past year, the company has seen revenue move from US$1.7 billion in Q4 2024 to US$2.2 billion in Q1 2026 and EPS shift from US$0.12 to US$0.18. This gives investors a clearer view of how recent quarters are feeding into the rolling totals. With margins edging higher and profits building on a trailing basis, this latest print sets up an earnings story that investors will judge on the durability of that profitability.

See our full analysis for Privia Health Group.

With the headline numbers on the table, the next step is to weigh them against the key narratives around Privia Health Group, highlighting where the data supports the current story and where expectations may need a reset.

59.3% TTM earnings growth vs modest revenue forecasts

• Trailing twelve month earnings grew 59.3% year over year on US$2.2b of revenue, while forward looking forecasts point to earnings growth of 28.9% per year and revenue growth of 9.4% per year.
• Consensus narrative points to expansion into new markets, value based care and technology investments as long term earnings drivers. However, the split between 28.9% expected earnings growth and 9.4% revenue growth means a lot of the bullish story rests on margins and contract quality rather than just higher patient volumes.
  • Demographic trends and the move to value based care fit with the trailing margin move from 0.8% to 1.1%, but investors still need that margin line to do most of the work if revenue is growing slower than the wider US market at 11.3%.
  • Expansion into new geographies like Arizona and a diversified payer mix are part of the bullish case, yet the Q1 2026 net income of US$3.1 million shows that current profitability is still measured in single digit millions on more than US$600 million of quarterly revenue.

Thin 1.1% margins and Q1 profit of US$3.1 million

• Net profit margin on a trailing basis is 1.1% on US$2.2b of revenue, while Q1 2026 net income was US$3.1 million on US$603.8 million of revenue.
• Bears focus on consolidation in healthcare, rising labor costs and heavier regulation as potential pressure points for a low margin model, and the current 1.1% margin leaves limited room for error if those headwinds show up in contract terms or staffing expenses.
  • Risks such as higher compliance costs, new payment models and possible shifts in bargaining power toward insurers and hospital systems all matter more when trailing net income is US$21.8 million against US$2.2b of revenue.
  • Dependence on adding providers and entering new markets, with the chance of higher acquisition costs or slower additions, could push selling and administrative costs higher, which would be felt quickly at a 1.1% margin level.

Do you want to see how skeptics think these thin margins could affect the long term story if growth slows, and where they believe the biggest pressure points are hiding in the model? 🐻 Privia Health Group Bear Case

P/E of 131.5x against DCF fair value of US$42.51

• Privia Health Group is trading on a trailing P/E of 131.5x compared with 25.2x for the US Healthcare industry and 26.8x for peers, while the current share price of US$23.99 sits below a DCF fair value of US$42.51 and below the analyst price target of US$31.80.
• Bulls argue that rapid earnings growth and expanding value based care justify paying well above sector P/E levels, and the gap between the US$23.99 share price, the US$42.51 DCF fair value and the US$31.80 analyst target is often cited as support for that view.
  • Strong trailing earnings growth of 59.3% and a five year annualized profit growth rate of 51.1% are the core data points bulls use to argue that a 131.5x P/E can be supported if those trends continue.
  • Analysts expecting earnings to reach US$90.9 million and EPS of US$0.65 by around 2029, with the stock trading at a P/E of 55.3x at that point, imply that a lot of future execution is already built into the current valuation.

Curious how supporters connect this rich 131.5x P/E and the gap to DCF fair value with the growth story in value based care and new markets, and what they think needs to go right for the stock price to move toward US$31.80 and beyond? 🐂 Privia Health Group Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Privia Health Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of growth hopes and thin margins feels finely balanced, quickly review the numbers yourself and weigh both sides of the argument. You can start with the 4 key rewards and 1 important warning sign

See What Else Is Out There

Privia Health Group currently combines very thin 1.1% margins with a P/E of 131.5x, so a lot of expectation is built into a small profit base.

If you are uneasy about paying up for a stock where profitability is tight and the valuation is rich, quickly compare it with 74 resilient stocks with low risk scores to find ideas that line up better with your comfort zone.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.